ScripThe market for BCMA-directed therapies to treat multiple myeloma just got a little more crowded with the US Food and Drug Administration giving the green light to Regeneron Pharmaceuticals’ Lynozyfic
ScripRegardless of the political turmoil at home and abroad this year, global biopharma companies’ and investors’ interest in South Korea appears to be intact or even growing, amid continued solid R&D
ScripAmgen’s updated Phase II data for MariTide in obesity may not have been the results the firm was looking for, but Amgen is trying to assure investors that based on learnings from an ongoing Phase II t
Pink SheetThe Biden Administration’s policies on price inflation rebates in Medicare and Medicaid unintentionally provided President Trump a tool to amplify the threat tariffs would pose to pharma. But Trump’s